BB BIOTECH AG

  • WKN: A0NFN3
  • ISIN: CH0038389992
  • Land: Switzerland

Nachricht vom 17.01.2020 | 07:00

BB Biotech AG closes the 2019 fiscal year with a profit

BB BIOTECH AG / Key word(s): Preliminary Results
BB Biotech AG closes the 2019 fiscal year with a profit

17-Jan-2020 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Media Release, January 17, 2020

BB Biotech AG closes the 2019 fiscal year with a profit

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its fiscal year 2019.

BB Biotech AG closed its fiscal year 2019 with a profit of approximately CHF 677 million, based on its preliminary unaudited consolidated results (CHF 471 million loss in the previous year).

As an investment company, the results reflect the performance of the stocks BB Biotech AG holds in its investment portfolio.

The publication of all relevant portfolio data will take place on January 17, 2020 at 7:00 am and the complete annual report will be published on February 21, 2020.


For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.


17-Jan-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

MBH Corporation. Hohes Kurspotenzial

Die MBH Corporation plc hat in den vergangenen Berichtsperioden eine sehr hohe M&A-Aktivität aufgezeigt. Unter Anwendung der so genannten Agglomeration Methodology hat die Beteiligungsgesellschaft branchenübergreifend seit 2018 11 Beteiligungen erworben. Bei einem Pro-Forma-Umsatz der Beteiligungsgesellschaften von über 120 Mio. GBP und einem Pro-Forma-EBITDA in Höhe von über 11 Mio. GBP weist die MBH derzeit eine Marktkapitalisierung von umgerechnet gerade einmal 19,8 Mio. GBP auf. Ausgehend vom aktuellen Aktienkurs liegt zu unserem Kursziel in Höhe von 1,95 € ein hohes Kurspotenzial vor

News im Fokus

Fresenius Medical Care kooperiert mit anderen Dialyseanbietern zur Bekämpfung der Coronavirus-Pandemie in den USA

01. April 2020, 09:01

Aktueller Webcast

SeaChange Corporation

Fourth Quarter Fiscal Year 2020 Results

06. April 2020

Aktuelle Research-Studie

KPS AG

Original-Research: KPS AG (von GBC AG): Buy

01. April 2020